Home

Mirum Pharmaceuticals, Inc. - common stock (MIRM)

67.93
+3.10 (4.78%)
NASDAQ · Last Trade: Aug 17th, 10:07 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close64.83
Open64.87
Bid55.15
Ask69.99
Day's Range64.33 - 69.00
52 Week Range36.86 - 69.00
Volume1,026,497
Market Cap2.60B
PE Ratio (TTM)-56.14
EPS (TTM)-1.2
Dividend & YieldN/A (N/A)
1 Month Average Volume659,148

Chart

About Mirum Pharmaceuticals, Inc. - common stock (MIRM)

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative treatments for rare liver diseases. The company aims to address significant unmet medical needs through its pipeline of novel therapeutic candidates, leveraging its expertise in drug discovery and development. Mirum's commitment to advancing patient care is evident in its efforts to deliver effective solutions that improve the quality of life for individuals suffering from conditions related to liver dysfunction. Through rigorous research and clinical studies, Mirum strives to contribute to the advancements in treatments that target these often overlooked diseases. Read More

News & Press Releases

Deep Dive Into Mirum Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)benzinga.com
Via Benzinga · August 8, 2025
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Surpasses Q2 2025 Estimates with Strong Revenue Growth and Raised Guidancechartmill.com
Mirum Pharmaceuticals beats Q2 2025 estimates with $127.8M revenue, narrows losses, and raises full-year guidance. Stock surges 8.6% post-earnings.
Via Chartmill · August 6, 2025
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · August 6, 2025
Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the second quarter 2025 and provided a business update.
By Mirum Pharmaceuticals, Inc. · Via Business Wire · August 6, 2025
Earnings Scheduled For August 6, 2025benzinga.com
Via Benzinga · August 6, 2025
Earnings Scheduled For May 7, 2025benzinga.com
Via Benzinga · May 7, 2025
Preview: Mirum Pharmaceuticals's Earningsbenzinga.com
Via Benzinga · May 6, 2025
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Fits Minervini’s Trend Template with Strong Growth Momentumchartmill.com
Mirum Pharmaceuticals (MIRM) fits Mark Minervini's trend-following strategy with strong technicals, revenue growth, and breakout potential. A high-growth momentum stock worth watching.
Via Chartmill · August 6, 2025
Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will report second quarter 2025 financial results on August 6, 2025. Mirum will also host a conference call to discuss the second quarter 2025 financial results and recent corporate progress.
By Mirum Pharmaceuticals, Inc. · Via Business Wire · July 30, 2025
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on July 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 14,460 shares of common stock and 7,220 restricted stock units (“RSUs”) to two new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
By Mirum Pharmaceuticals, Inc. · Via Business Wire · July 10, 2025
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 115,620 shares of common stock and 57,740 restricted stock units (“RSUs”) to 10 new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
By Mirum Pharmaceuticals, Inc. · Via Business Wire · June 10, 2025
Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies.
By Mirum Pharmaceuticals, Inc. · Via Business Wire · May 19, 2025
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:
By Mirum Pharmaceuticals, Inc. · Via Business Wire · May 14, 2025
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 9, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 53,230 shares of common stock and 26,585 restricted stock units (“RSUs”) to eight new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stockbenzinga.com
Via Benzinga · May 9, 2025
Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today presented new data from its Phase 2b VANTAGE study at the European Association for the Study of the Liver (EASL) meeting in Amsterdam, the Netherlands. The VANTAGE study is evaluating volixibat in patients with cholestatic pruritus caused by primary biliary cholangitis (PBC).
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the first quarter 2025 and provided a business update.
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2025 financial results on Wednesday, May 7, 2025. Mirum will also host a conference call to discuss the first quarter 2025 financial results and recent corporate progress.
By Mirum Pharmaceuticals, Inc. · Via Business Wire · April 30, 2025
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present data at three upcoming medical congresses. Digestive Disease Week (DDW) will be held in San Diego, May 3-6, 2025. The European Association for the Study of the Liver (EASL) will take place May 7-10 in Amsterdam, the Netherlands. The 57th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting will follow May 14-17 in Helsinki, Finland. Data from Mirum’s LIVMARLI and volixibat studies will be highlighted in oral and poster presentations during the congresses.
By Mirum Pharmaceuticals, Inc. · Via Business Wire · April 28, 2025
FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullishstocktwits.com
Livmarli tablets will be available in June through Mirum Access Plus pharmacy.
Via Stocktwits · April 14, 2025
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC).
By Mirum Pharmaceuticals, Inc. · Via Business Wire · April 14, 2025
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 39,740 shares of common stock and 19,830 restricted stock units (“RSUs”) to seven new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
By Mirum Pharmaceuticals, Inc. · Via Business Wire · April 10, 2025
LIVMARLI Now Approved in Japan for ALGS and PFIC
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that its partner, Takeda Pharmaceutical Company Limited, has received approval by the Japanese Ministry of Health, Labour, and Welfare for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) in Japan.
By Mirum Pharmaceuticals, Inc. · Via Business Wire · March 27, 2025
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 17,620 shares of common stock and 9,290 restricted stock units (“RSUs”) to five new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
By Mirum Pharmaceuticals, Inc. · Via Business Wire · March 10, 2025
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update.
By Mirum Pharmaceuticals, Inc. · Via Business Wire · February 26, 2025